NCT04286750

Study in Healthy Subjects to Examine the Safety and Tolerability of ACT-1004-1239 Given as Multiple, Gradually Increasing Doses and to Examine the Effects of ACT-1004-1239 on the Body and the Way the Body Takes up, Distributes, and Gets Rid of ACT-1004-1239

Randomized, Double-blind, Placebo-controlled, Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-ascending Doses of ACT-1004-1239 in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: Idorsia Pharmaceuticals Ltd. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

Study in healthy subjects to examine the safety and tolerability of ACT-1004-1239 given as multiple, gradually increasing doses and to examine the effects of ACT-1004-1239 on the body and the way the body takes up, distributes, and gets rid of ACT-1004-1239

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	ACT-1004-1239	ACT-1004-1239 administered as hard capsules for oral use.
DRUG	Placebo	Matching placebo administered as hard capsules for oral use.

Timeline

• Start date: 2020-07-11
• Primary completion: 2020-09-25
• Completion: 2020-09-25
• First posted: 2020-02-27
• Last updated: 2021-01-20

Locations

1 site across 1 country: Portugal